ArticleInternational journal of cancer2020
Impact of screening on cervical cancer incidence: A population-based case-control study in the United States.
Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Effect of Organized Cervical Cancer Screening Programs on Incidence and Mortality: A Systematic Review and Meta-analysis.Journal of prevention (2022) · 2026Pooled it
- Screening for the prevention and early detection of cervical cancer: systematic reviews to inform an update to recommendations by the Canadian Task Force on Preventive Health Care.Systematic reviews · 2025Pooled it
- Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus-Associated Cancers.The Journal of molecular diagnostics : JMD · 2024Pooled it
- Exposure Definition in Case-Control Studies of Cervical Cancer Screening: A Systematic Literature Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Pooled it
- HPV-Related Disease: Gynecologists' Leadership in Patient-Centered Multidisciplinary Care.Cancers · 2026Article
- Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support.Diagnostics (Basel, Switzerland) · 2026Review
- Strategies to Raise Awareness About Screening and Vaccination for the Human Papillomavirus Among Women in Limpopo Province, South Africa.International journal of environmental research and public health · 2026Article
- Update of incidence and survival in patients with cervical cancer in the United States from 2000 to 2021.Journal of gynecologic oncology · 2026Article
- Utilization and outcomes of serial cervical cancer screening in a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in a non-Medicaid expansion state.Cancer causes & control : CCC · 2025Article
- Exploring Cervical Cancer Screening Uptake among Women in the United States: Impact of Social Determinants of Health and Psychosocial Determinants.Behavioral sciences (Basel, Switzerland) · 2024Article
- Anogenital HPV-Related Cancers in Women: Investigating Trends and Sociodemographic Risk Factors.Cancers · 2024Article
- Cervical cancer in Thailand: 2023 update.Obstetrics & gynecology science · 2024Article
- Evolution of Pathological Techniques for the Screening of Cervical Cancer: A Comprehensive Review.Cureus · 2024Review
- How do young women approaching screening age interpret the NHS cervical screening leaflet? A mixed methods study of identifying interpretation difficulties, barriers, facilitators, and leaflet interpretation, engagement and future screening behaviour.Health psychology and behavioral medicine · 2024Article
- Utilization of cervical cancer screening services and its associated factors in Iran: a case-control study.Infectious agents and cancer · 2023Article
- Clinical Performance of the RealTiMicrobiology spectrum · 2022Article
- Effectiveness of Cervical Testing in and outside a Screening Program-A Case-Control Study.Cancers · 2022Article
- Article
- Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions.medRxiv : the preprint server for health sciences · 2022Article
- Trends in cervical cancer incidence and mortality of young and middle adults in Japan.Cancer science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
Abstract
Cervical cancer is widely preventable through screening, but little is known about the duration of protection offered by a negative screen in North America. A case-control study was conducted with records from population-based registries in New Mexico. Cases were women diagnosed with cervical cancer in 2006-2016, obtained from the Tumor Registry. Five controls per case from the New Mexico HPV Pap Registry were matched to cases by sex, age and place of residence. Dates and results of all cervical screening and diagnostic tests since 2006 were identified from the pap registry. We estimated the odds ratio of nonlocalized (Stage II+) and localized (Stage I) cervical cancer associated with attending screening in the 3 years prior to case-diagnosis compared to women not screened in 5 years. Of 876 cases, 527 were aged 25-64 years with ≥3 years of potential screening data. Only 38% of cases and 61% of controls attended screening in a 3-year period. Women screened in the 3 years prior to diagnosis had 83% lower risk of nonlocalized cancer (odds ratio [OR] = 0.17, 95% CI: 0.12-0.24) and 48% lower odds of localized cancer (OR = 0.52, 95% CI: 0.38-0.72), compared to women not screened in the 5 years prior to diagnosis. Women remained at low risk of nonlocalized cancer for 3.5-5 years after a negative screen compared to women with no negative screens in the 5 years prior to diagnosis. Routine cervical screening is effective at preventing localized and nonlocalized cervical cancers; 3 yearly screening prevents 83% of nonlocalized cancers, with no additional benefit of more frequent screening. Increasing screening coverage remains essential to further reduce cervical cancer incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.